Jean Jacques Bienaime Buys 5,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 5,000 shares of the stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the transaction, the director owned 43,415 shares of the company’s stock, valued at approximately $898,690.50. The trade was a 13.02% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The shares were acquired at an average price of $21.55 per share, with a total value of $21,550.00.

Immunome Stock Performance

Shares of Immunome stock opened at $19.90 on Tuesday. The company has a market capitalization of $2.25 billion, a P/E ratio of -8.36 and a beta of 2.11. Immunome, Inc. has a 1 year low of $7.74 and a 1 year high of $27.65. The company’s fifty day moving average is $21.94 and its two-hundred day moving average is $21.24.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts expect that Immunome, Inc. will post -2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IMNM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Truist Financial raised Immunome to a “strong-buy” rating in a report on Monday, May 4th. Leerink Partners cut their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday. Craig Hallum increased their price target on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Stephens lowered their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.82.

Institutional Trading of Immunome

A number of institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. increased its holdings in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after acquiring an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Immunome in the 4th quarter worth approximately $30,710,000. Finally, Sofinnova Investments Inc. increased its stake in Immunome by 271.2% in the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.